Canada Administers First Alzheimer’s Infusion, Signaling Hope

Sharon Runge has made history as the first patient in Canada to receive an infusion of Lecanemab, a newly approved drug aimed at fighting Alzheimer’s disease. This significant milestone took place on March 15, 2024, marking a pivotal moment for those affected by the condition and their families across the country.

Dr. Sara Mitchell, a cognitive neurologist, emphasized the importance of this development. “It’s a historic moment for people living with Alzheimer’s disease and their families in Canada because we have been able to meaningfully intervene in this disease,” she stated. Canada has now become the last of the G7 nations to approve this monoclonal antibody, which works by removing harmful amyloid plaques from the brain. Clinical data suggests that Lecanemab can slow the progression of Alzheimer’s by approximately 30 percent.

Impact on Patients and Families

The implications of this treatment are profound. According to Dr. Mitchell, long-term data indicates that patients taking Lecanemab can potentially extend their independent living by up to one year over a four-year period. This prospect offers renewed hope to families grappling with the increasing dependence that often accompanies Alzheimer’s.

For Dallard Runge, Sharon’s husband, the approval of Lecanemab presents a chance to reclaim precious time with his wife. “In the last year or so, Sharon was diagnosed with Alzheimer’s. My hope is that this drug delays the further onset of the disease for a while for us,” he remarked. “The longer we have together, the more happiness we’ll get to share.”

While Health Canada has approved the drug, it has not yet received a funding recommendation from the Canada Drug Administration. Consequently, provincial health agencies have not provided coverage for Lecanemab, leaving families like the Runges to bear the financial burden. The total cost for biweekly infusions can reach approximately $32,000 annually, subject to fluctuations based on individual patient weight.

Dr. Mitchell advocates for equitable access to this treatment, stressing the importance of government support. “There are people that you’ll see every day on the street who have this disease and who want to keep living independently. That’s who this drug is for,” she explained.

Public Reception and Future Research

Despite the optimism surrounding Lecanemab, some public resistance has emerged concerning taxpayer funding for such expensive treatments. In response, Dallard expressed empathy for skeptics, stating, “I’d say they should walk in our shoes.” He added that he wishes his wife could have started treatment sooner, as she began displaying early symptoms of Alzheimer’s four years ago.

Medical professionals assert that early intervention is crucial. The proteins that contribute to Alzheimer’s can accumulate in the brain long before any symptoms appear. The next phase of research will involve testing whether Lecanemab can also benefit asymptomatic patients who have harmful plaque but are not yet experiencing symptoms.

Just moments before receiving her first infusion, Sharon shared her struggle with understanding her diagnosis. “In my day-to-day life, I feel like I’m fine,” she said with a smile. Dallard noted that while her short-term memory has been gradually declining, her love for her family remains steadfast. “I’m so fortunate to have met him,” Sharon said of Dallard, highlighting the profound bond they share.

The Runges now hold onto hope that their life together will be enriched with additional time thanks to this groundbreaking treatment. As the first infusion of Lecanemab is administered in Canada, it represents not just a medical advancement but a beacon of hope for countless families facing the challenges of Alzheimer’s disease.